Progression-free Survival (PFS) one year [clinicaltrials_resource:c59853c83a8a19406628a80c43a2f81d]
The primary endpoint is the progression-free survival (PFS) defined as the time from start of treatment to first documentation of objective tumor progression or to death due to any cause, whichever occurs first during treatment or follow-up period. For patients not known to have died as of the data cut-off date and who do not have objective progressive disease, PFS will be censored at the date of the last objective progression-free disease assessment. For patients who receive subsequent anticancer therapy (after discontinuation from the study drug) prior to objectively determined disease progression or death, PFS will be censored at the date of the last objective progression-free disease assessment prior to post-discontinuation anti-cancer therapy. Acceptable documentation of objective disease progression status consists of objective assessments using CT scan assessment method.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Progression-free Survival (PFS) one year [clinicaltrials_resource:c59853c83a8a19406628a80c43a2f81d]
The primary endpoint is the progression-free survival (PFS) defined as the time from start of treatment to first documentation of objective tumor progression or to death due to any cause, whichever occurs first during treatment or follow-up period. For patients not known to have died as of the data cut-off date and who do not have objective progressive disease, PFS will be censored at the date of the last objective progression-free disease assessment. For patients who receive subsequent anticancer therapy (after discontinuation from the study drug) prior to objectively determined disease progression or death, PFS will be censored at the date of the last objective progression-free disease assessment prior to post-discontinuation anti-cancer therapy. Acceptable documentation of objective disease progression status consists of objective assessments using CT scan assessment method.
Bio2RDF identifier
c59853c83a8a19406628a80c43a2f81d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c59853c83a8a19406628a80c43a2f81d
measure [clinicaltrials_vocabulary:measure]
Progression-free Survival (PFS)
time frame [clinicaltrials_vocabulary:time-frame]
description
The primary endpoint is the pr ...... ing CT scan assessment method.
identifier
clinicaltrials_resource:c59853c83a8a19406628a80c43a2f81d
title
Progression-free Survival (PFS) one year
@en
type
label
Progression-free Survival (PFS ...... 853c83a8a19406628a80c43a2f81d]
@en